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14,15-Leukotriene & is a pivotal biosynthetic intermediate in 15-lipoxygenase initiated leukotriene 
biosynthesis. This compound hydrolyzes instantaneously in phosphate buffer at pH 7.4. However, 
addition of human or bovine albumin to otherwise identical buffer solutions increases its stability. Intact 
14,lWeukotriene & then decomposes by first-order kinetics with rate constants inversely proportional to 
the albumin concentration. Stabilization of 14,15_leukotriene & under certain conditions may influence 
its proportionate transformation by enzymatic vs non-enzymatic processes. 
14, IS-Oxido-5,8,10,12-eicosatetraenoic acid 
Bovine serum albumin 
1. INTRODUCTION 
In certain cells 15hydroperoxy-5,8,10,13-eico- 
satetraenoic acid (15-HPETE) is a lipoxygenase 
metabolite of arachidonic acid [ 1,2]. Dehydration 
of 15-HPETE generates 14,15-oxido-5,8,10,12-eico- 
satetraenoic acid, designated 14,15-leukotriene A4 
(14,15-LT&) [3]. The latter compound is a transient 
biosynthetic precursor for other leukotrienes such 
as isomeric 8,15-dihydroxy-5,9,11,13-eicosatetra- 
enoic acids and 14,15-dihydroxy-5,8,10,12-eicosa- 
tetraenoic acids [4,5]. 14,15-LTA4 and its metabo- 
lites resemble, in some respects, the leukotrienes 
formed via 5-lipoxygenase metabolism of arachi- 
donic acid [6]. However, in contrast to 5,6-LT&, 
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less is known about 14,15-LT& and some dissimi- 
larities exist between the corresponding systems of 
products derived from these compounds. For in- 
stance, some enzymatic features of the metabolism 
of 14,15-LTA4 are uncertain [3,5,7,8]. Since 
14,15-LT& contains an allylic epoxide susceptible 
to rapid non-enzymatic hydrolysis we evaluated its 
stability under selected conditions. The results indi- 
cate that human and bovine serum albumin prolong 
its half-life to a significant degree under conditions 
that otherwise favor its rapid hydrolysis. 
2. EXPERIMENTAL 
2.1. Materials 
PRP-lR polymer reversed phase HPLC columns 
were obtained from Hamilton, Reno, NE. Bovine 
serum albumin (BSA), essentially fatty acid free 
(Sigma, St Louis) or crystalline (Armour Pharma- 
ceutical, Eastbourne, England); and human serum 
albumin (HSA), crystalline (Kabi, Stockholm), 
>98% pure were used as received. 15-Hydroper- 
oxyeicosatetraenoic acid (15-HPETE) was prepared 
as in [3]. 14,15-Oxide-5,8,10,1Zeicosatetraenoic 
acid (14,15-LTA4) was chemically synthesized using 
15-HPETE methyl ester as a starting material [9]. 
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2.2. Stability determination procedure 
Phosphate buffer (0.10 M, pH 7.4) containing 
HSA or BSA (l-10 mg/ml) was equilibrated at 4 
or 25°C; then 2.0 ml were mixed with 14,15-LTA4 
(1Opg) dissolved in tetrahydrofuran (5,ul). Samples 
(200~1) were withdrawn at appropriate intervals 
for immediate RP-HPLC quantitation of intact 
14,15-LT&. 
2.3. Quantitation of intact 14,lUeukotriene Ad 
Intact 14,15-LTA4 was determined by RP- 
HPLC [lo]. Samples (100~1) were chromato- 
graphed on a PRP-lR polymer reversed phase 
column, eluted at 1 .O ml/min with 0.01 M acetoni- 
trile (pH 9.5)/sodium borate (35 : 65, v/v). Quanti- 
tation was based on spectrophotometric detection 
at 280 nm. Intact 14,15-LT& eluted with an 
approximate retention time of 7 min. Dihydroxy- 
leukotrienes formed by non-enzymatic hydrolysis 
of 14,15-LT& had retention times between 2 and 
4min and did not interfere with the analysis. The 
half-life of 14,15-LT& in the mobile phase ex- 
ceeded 60min at 25°C; therefore, decomposition 
was less than 3% during its chromatographic 
transit. Half-life and rate constants were based on 
peak height measurements. 
3. RESULTS 
When the allylic epoxide 14,15-LT& was added 
to 0.10 M phosphate buffer (pH 7.4) it degraded 
instantaneously. Within 15 s no intact epoxide was 
detected by HPLC. When human albumin was 
added to the same buffer the stability of 14,15- 
LT& (5pg/ml) was greatly increased. Fig. 1 shows 
its half-lives at 4 and 25°C as a function of albu- 
min concentration. Significant stabilization occur- 
red with as little as 1 mg/ml HSA. For instance, 
half-lives increased to 7.0 + 1.4 and 62.4 f 8.3 min 
at 25 and 4”C, respectively. The stabilizing effect 
reached a plateau at 10 mg/ml HSA. It is notable 
that these concentrations of albumin are below 
normal plasma levels of 35-50mg/ml. In all ex- 
periments 14,15-LTA4 decomposed by first-order 
kinetics with rate constants inversely proportional 
to the albumin content and proportional to the 
temperature (fig.2). There was no qualitative dif- 
ference in the hydrolysis products formed from 
14,15-LT& in the presence or absence of albumin. 
At a constant albumin concentration and tempera- 
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Fig. 1. Effect of HSA on 14,15-LT& stability. Values 
represent half-life (mean f SD for 23 experiments) at 
4°C (o--o) and 25°C (c+-+) as a function of the 
albumin content of 0.10 M phosphate buffer (pH 7.4). 
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Fig.2. Decomposition kinetics of 14,15-LT& at 4°C 
(top panel) and 25°C (lower panel). Values shown are 
representative xperiments for albumin concentrations 
of 1 (M), 2 (O--U), 5 (M) and 10 (C--O) 
mg/ml. 
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Table 1 
Effect of human and bovine albumin on the stability of 14,15_leukotriene -4 
Albumin HSA BSA 
concentration 
(mg/ml) 4°C 25°C 4OC 25°C 
1 62.4 f 8.3 7.0 f 1.4 12.4 + 2.4 11 .O f 2.9 
2 232.0 f 35.6 12.9 + 2.0 173.3 f 4.0 16.9 f 2.4 
5 574.0 f 19.0 20.4 f 2.5 298.1 It: 10.3 19.5 f 1.3 
10 700.0 j, 70.7 25.8 f 4.6 311.6* 9.8 22.9 f 2.7 
Values represent half-lives (mean f SD, n 1 3 experiments) of 14,15-LT&, initial concentra- 
tion 5 pg/ml 
ture the stabilizing effect also increased with pH. 
For example, at 4°C in 0.20M buffers containing 
I mg/ml HSA the half-lives of 14,15-LT& were 
9.0, 27.6, 62.4, 127.8 and 704.7min at pH6, 7, 
7.4, 8 and 9, respectively. 
Several drugs reduced the stabilizing effect of 
albumin to varying degrees. Preincubation of HSA 
(1 mg/ml) in 0.10 M phosphate buffer (pH 7.4) with 
phenylbutazone, nordihydroguaiaretic acid, aspirin 
and warfarin for 1 h at 37°C at a ligand : albumin 
mole ratio of 10: 1 reduced the half-life of 14,15- 
LT~from62.4~8.3to37.5,28.1,43.4~35.5min, 
respectively. Atropine sulfate had no effect. 
Stabilization of 14,15-LT& was evident with 
albumin from different species. Table 1 compares 
its half-lives in the presence of HSA and BSA 
(l-lOmg/ml) at 4 and 25°C. 
4. DISCUSSION 
We show here that an unstable allylic epoxide, 
14,15-oxido-5,8,10,12-eicosatetraenoic ac d, an in- 
termediate in the leukotriene cascade is stabilized 
by albumin, especially HSA. This stabilizing effect 
was pH, concentration and temperature depen- 
dent. A similar effect of albumin has previously 
been described for several other unstable arachi- 
donic acid metabolites [ 10-131. Certain drugs 
reduced the stabilizing capacity of HSA. Most 
effective were phenylbutazone, warfarin and nor- 
dihydroguaiuretic acid. Acetylsalicyclic acid had a 
small effect and atropine did not reduce the stability 
at all. These results are in accordance with pre- 
vious data found for TXAz and 5,6-LTA4 and they 
provide further evidence for the hypothesis that 
the binding site of albumin for drugs such as 
phenylbut~one and warfarin could be involved in 
this stabilizing effect. 
Many of the important compounds in the ara- 
chidonic acid metabolic cascade are chemically un- 
stable. These unstable compounds can have either 
a direct biological activity, like TXAz or PGG, or 
they can act as precursors for other biologically 
important products as is the case with LT&. 
Therefore, factors that influence the stability of 
these compounds are important because they can 
change the relative amounts of different metabo- 
lites and enhance or prolong their biological 
impact. Our data provide further evidence that 
albumin might play such a role in arachidonic acid 
metabolism. From a practical perspective, the 
stabilization of 14,15-LTA4 with albumin has been 
useful to trap this compound, in its intact form, 
momentarily during experiments to elucidate alter- 
native pathways of its biosynthetic origin [14]. 
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